IMC-002(Immuneoncia)

N/A

Report date: 2025/10/24 20:00:54

Base Information

Drug NameIMC-002(Immuneoncia)
Drug Alias NameIMC-0023D-1973D197
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionCluster of differentiation 47 inhibitors
TargetsCluster of differentiation 47
Therapy Area/IndicationsSolid tumoursNeuromyelitis OpticaNeoplasm Metastasis +[7
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth KoreaMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesImmuneoncia Therapeutics Inc
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsSolid tumoursNeuromyelitis OpticaNeoplasm Metastasis +[6
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A